ALZCUR AlzeCure Pharma AB (publ)

0.5748USD5.840 SEK · STO-4.26%Mkt Cap: 66.06M USDP/E: 8.46

AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involv…

Key Statistics

Company
Market Cap66.06M USD
Enterprise Value56.61M USD
Revenue (TTM)16.09M USD
Gross Profit9.58M USD
Net Income (TTM)-4.69M USD
Revenue/Share0.13 USD
Last Price0.5748 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees10
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0010133785
Valuation
P/E (Trailing)8.46
P/E (Forward)-48.67
PEG—
EV/EBITDA5.88
EV/Revenue3.52
P/S4.10
P/B3.69
EPS (TTM)0.07 USD
EPS (Forward)-0.01 USD
52W Range
0.128062% of range0.8544
52W High0.8544 USD
52W Low0.1280 USD
Profitability
Gross Margin100.00%
Oper. Margin59.10%
EBITDA Margin59.84%
Profit Margin31.56%
ROE-144.75%
ROA-80.71%
ROIC—
ROCE-135.19%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.40M USD
CapEx (TTM)—
FCF Margin40.56%
FCF Yield9.88%
Net Debt-22.66M USD
Net Debt/EBITDA-2.35
Net Debt/FCF-3.47
Balance Sheet
Debt/Equity0.08
Current Ratio12.79
Quick Ratio12.72
Book Value/Sh0.16 USD
Cash/Share0.17 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)1.280 USD
Upside (mean)+122.6%
Target Range1.280 USD – 1.280 USD
# Analysts1
Ownership
Shares Out.114.91M
Float92.15M
Insiders32.99%
Institutions10.57%
Technical
SMA 500.6850 (-16.1%)
SMA 2000.4381 (+31.2%)
Beta-0.16
S&P 52W Chg12.00%
Avg Vol (30d)207.13K
Avg Vol (10d)227.74K
Technical Indicators
RSI (14)32.2
MACD-0.1964
MACD Signal-0.1852
MACD Hist.-0.0111
BB Upper0.6631 USD
BB Middle0.6220 USD
BB Lower0.5808 USD
BB Width13.24%
ATR (14)0.0382 USD
Vol Ratio (20d)0.98x

About AlzeCure Pharma (STO: ALZCUR)

›

AlzeCure Pharma (STO: ALZCUR) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 10 employees.

The shares were at 5.840 SEK on 19 November 2026, up 193.5% over 52 weeks. Its 52-week range is 1.300 SEK to 8.680 SEK: the price is 32.7% below the high and 349.2% above the low.

At a market capitalisation of 671.10M SEK, it trades at 8.5 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 75% for ALZCUR.

AlzeCure Pharma reports return on equity of -144.8% and an operating margin of 59.1%.

It holds more cash than debt, a net cash position of 230.22M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 13.00 SEK is 122.6% above the current price.